NEW YORK ( TheStreet) -- Bristol-Myers Squibb Company (NYSE: BMY) hit a new 52-week high Monday as it is currently trading at $32.78, above its previous 52-week high of $32.75 with 1.3 million shares traded as of 10:05 a.m. ET. Average volume has been 14.7 million shares over the past 30 days.

Bristol-Myers Squibb has a market cap of $55.8 billion and is part of the health care sector and drugs industry. Shares are up 23.6% year to date as of the close of trading on Friday.

Bristol-Myers Squibb Company, a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. The company has a P/E ratio of 17, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
  • Practice your BMY trading strategies and win cash in our stock game.

TheStreet Ratings rates Bristol-Myers Squibb as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Bristol-Myers Squibb Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.